The antioxidant N-acetylcysteine promotes atherosclerotic plaque stabilization through suppression of rage, MMPs and NF-κB in ApoE-deficient Mice

Journal of Atherosclerosis and Thrombosis

Volumn 18, Issue 11, 2011, Pages 998-1008

  Lu, Yonggang ^a,b   Qin, Weiwei ^c   Shen, Tao ^b   Dou, Lin ^a,b   Man, Yong ^b   Wang, Shu ^b   Xiao, Chuanshi ^c   Li, Jian ^a,b  

^a GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

^b BEIJING HOSPITAL   (China)

^c SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Matrix metalloproteinases; N acetylcysteine; Nuclear factor kappa B; Receptor of advanced glycation end products

Indexed keywords

ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIOXIDANT; APOLIPOPROTEIN E; GELATINASE A; GELATINASE B; GLUCOSE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; MATRIX METALLOPROTEINASE; REACTIVE OXYGEN METABOLITE; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ROOT; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DOWN REGULATION; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIPID BLOOD LEVEL; LIPID STORAGE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 82455164407     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.8870     Document Type: Article

References (38)

1. Stoll G, Bendszus M: Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke, 2006; 37: 1923-1932
2. Newby AC, George SJ, Ismail Y, Johnson JL, Sala-Newby GB, Thomas AC: Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost, 2009; 101: 1006-1011
3. Spagnoli LG, Bonanno E, Sangiorgi G, Mauriello A: Role of inflammation in atherosclerosis. J Nucl Med, 2007; 48: 1800-1815
4. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuc-curullo C, de Cesare D, de blasis G, Muraro R, Bei R, Chiarelli F, Marie Schmidt A, Cuccurullo F, Mezzetti A: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glyce-mic control. Circulation, 2003; 108: 1070-1077
5. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human athero-sclerotic plaques. J Clin Invest, 1994; 94: 2493-2503
6. Naylor R, Cuffe RL, Rothwell PM, Loftus IM, Bell PR: A systematic review of outcome following synchronous carotid endarterectomy and coronary artery bypass: influ-ence of surgical and patient variables. Eur J Vasc Endovasc Surg, 2003; 26: 230-241
7. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, de Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chi-arelli F, Cuccurullo F, Mezzetti A: Overexpression of func-tionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation, 2001; 104: 921-927
8. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD: RAGE: a potential target for Abeta-mediated cel-lular perturbation in Alzheimer's disease. Curr Mol Med, 2007; 7: 735-742
9. Naka Y, Bucciarelli LG, Wendt T, Lee LK, Rong LL, Ramasamy R, Yan SF, Schmidt AM: RAGE axis: Animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol, 2004; 24: 1342-1349
10. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, Kalea AZ, Lu Y, Rosario RH, Oruganti S, Nikolla Z, Belov D, Lalla E, Ramasamy R, Yan SF, Schmidt AM: Vascular and inflammatory stresses mediate atherosclero-sis via RAGE and its ligands in apoE-/- mice. J Clin Invest, 2008; 118: 183-194
11. Sun L, Ishida T, Yasuda T, Kojima Y, Honjo T, Yamamoto Y, Yamamoto H, Ishibashi S, Hirata K, Hayashi Y: RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-defi-cient mice. Cardiovasc Res, 2009; 82: 371-381
12. Goldin A, Beckman JA, Schmidt AM, Creager MA: Advanced glycation end products: sparking the develop-ment of diabetic vascular injury. Circulation, 2006; 114: 597-605
13. Basta G, Schmidt AM, de Caterina R: Advanced glyca-tion end products and vascular inflammation: implica-tions for accelerated atherosclerosis in diabetes. Cardio-vasc Res, 2004; 63: 582-592
14. Zhang F, Kent KC, Yamanouchi D, Zhang Y, Kato K, Tsai S, Nowygrod R, Schmidt AM, Liu B: Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg, 2009; 250: 416-423
15. Radomska-Le ́niewska DM, Skopin ́ska-Rózewska E, Jankowska-Steifer E, Sobiecka M, Sadowska AM, Hevelke A, Malejczyk J: N-acetylcysteine inhibits IL-8 and MMP-9 release and ICAM-1 expression by bronchoalveo-lar cells from interstitial lung disease patients. Pharmacol Rep, 2010; 62: 131-138
16. Ivanovski O, Szumilak D, Nguyen-Khoa T, Ruellan N, Phan O, Lacour B, descamps-Latscha B, Drüeke TB, Massy ZA: The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int, 2005; 67: 2288-2294
17. Zuckerman SH, Evans GF, Schelm JA, Eacho PI, Sandusky G: Estrogen-mediated increases in LDL cholesterol and foam cell-containing lesions in human ApoB100xCETP transgenic mice. Arterioscler Thromb Vasc Biol, 1999; 19: 1476-1483
18. Tekabe Y, Li Q, Rosario R, Sedlar M, Majewski S, Hud-son BI, Einstein AJ, Schmidt AM, Johnson LL: Develop-ment of receptor for advanced glycation end products-directed imaging of atherosclerotic plaque in a murine model of spontaneous atherosclerosis. Circ Cardiovasc Imaging, 2008; 1: 212-219
19. Galis ZS, Asanuma K, Godin D, Meng X: N-acetyl-cyste-ine decreases the matrix-degrading capacity of macro-phage-derived foam cells: new target for antioxidant ther-apy? Circulation, 1998; 97: 2445-2453
20. Adiguzel E, Ahmad PJ, Franco C, Bendeck MP: Colla-gens in the progression and complications of atherosclero-sis. Vasc Med, 2009; 14: 73-89
21. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol, 2006; 26: 1120-1125
22. Choi ET, Collins ET, Marine LA, Uberti MG, Uchida H, Leidenfrost JE, Khan MF, Boc KP, Abendschein DR, Parks WC: Matrix metalloproteinase-9 modulation by resident arterial cells is responsible for injury-induced accelerated atherosclerotic plaque development in apoli-poprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 2005; 25: 1020-1025
23. Gough PJ, Gomez IG, Wille PT, Raines EW: Macrophage expression of active MMP-9 induces acute plaque disrup-tion in apoE-deficient mice. J Clin Invest, 2006; 116: 59-69
24. Tedgui A, Mallat Z: Cytokines in atherosclerosis: patho-genic and regulatory pathways. Physiol Rev, 2006; 86: 515-581
25. dekhuijzen PN: Antioxidant properties of N-acetylcyste-ine: their relevance in relation to chronic obstructive pul-monary disease. Eur Respir J, 2004; 23: 629-636
26. Hunninghake GW: Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med, 2005; 353: 2285-2287
27. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lan-caster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm KA: Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes, 2008; 57: 2461-2469
28. Yamagishi S, Inagaki Y, Amano S, Okamoto T, Takeuchi M, Makita Z: Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative proper-ties. Biochem Biophys Res Commun, 2002; 296: 877-882
29. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Klöting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Häring HU, Schleicher E, Nawroth PP: Diabetes-associated sustained activation of the transcription factor nuclear factor-DκB. Diabetes, 2001; 50: 2792-2808
30. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pin-sky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A: Survey of the distribution of a newly characterized recep-tor for advanced glycation end products in tissues. Am J Pathol, 1993; 143: 1699-1712
31. Goldin A, Beckman JA, Schmidt AM, Creager MA: Advanced glycation end products: sparking the develop-ment of diabetic vascular injury. Circulation, 2006; 114: 597-605
32. Cuccurullo C, Iezzi A, Fazia ML, de Cesare D, Di Francesco A, Muraro R, Bei R, Ucchino S, Spigonardo F, Chi-arelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Cipol-lone F: Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterio-scler Thromb Vasc Biol, 2006; 26: 2716-2723
33. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuc-curullo C, de Cesare D, de Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A: The receptor RAGE as a progression factor amplifying arachi-donate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic con-trol. Circulation, 2003; 108: 1070-1077
34. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM: RAGE blockade stabilizes estab-lished atherosclerosis in diabetic apolipoprotein E-null mice. Circulation, 2002; 106: 2827-2835
35. Yao D, Brownlee M: Hyperglycemia-Induced Reactive Oxygen Species Increase Expression of the Receptor for Advanced Glycation End Products (RAGE) and RAGE Ligands. Diabetes, 2010; 59, 249-255
36. Figarola JL, Shanmugam N, Natarajan R, Rahbar S: Anti-inflammatory effects of the advanced glycation end prod-uct inhibitor LR-90 in human monocytes. Diabetes, 2007; 56: 647-655
37. Tang D, Kang R, Zeh HJ, Lotze MT: High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal, 2011; 14: 1315-1335
38. Li J, Schmidt AM: Characterization and functional analy-sis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem, 1997; 272: 16498-16506